Quanterix Corp Stock Research

Market Summary

USD19.80-0.99

Market Closed

-4.76%

QTRX Alerts

Big jump in Earnings (Y/Y)
Losses in recent quarter

QTRX Stock Price

QTRX RSI Chart

QTRX Valuation

Market Cap

741.0M

Price/Earnings (Trailing)

-8.75

Price/Sales (Trailing)

7.1

EV/EBITDA

-5.55

Price/Free Cashflow

-15.92

QTRX Price/Sales (Trailing)

QTRX Profitability

Operating Margin

44.36%

EBT Margin

-91.58%

Return on Equity

-26.94%

Return on Assets

-22.27%

Free Cashflow Yield

-6.28%

QTRX Fundamentals

QTRX Revenue

Revenue (TTM)

104.4M

Revenue Y/Y

-3.71%

Revenue Q/Q

10.19%

QTRX Earnings

Earnings (TTM)

-84.7M

Earnings Y/Y

66.38%

Earnings Q/Q

67.15%

Price Action

52 Week Range

6.3123.44

(Low)(High)

Last 7 days

-5.7%

Last 30 days

56.7%

Last 90 days

87.7%

Trailing 12 Months

10.4%

QTRX Financial Health

Current Ratio

12.32

QTRX Investor Care

Shares Dilution (1Y)

1.42%

Diluted EPS (TTM)

-2.27

Peers (Alternatives to Quanterix)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
A	34.8B	6.9B	-13.07%	-9.66%	26.34	5.03	7.53%	9.79%
ILMN	30.7B	4.4B	-5.38%	-24.63%	-6.98	6.91	-4.49%	-677.95%
MTD	29.8B	4.0B	-11.85%	-0.89%	33.62	7.55	3.66%	11.80%
WAT	15.1B	3.0B	-14.91%	-23.72%	21.9	5.09	3.42%	-2.23%
PKI	14.9B	3.4B	-15.95%	-22.45%	15.51	4.44	-23.30%	29.82%
MID-CAP
SMALL-CAP
PACB	3.1B	128.3M	16.42%	100.00%	-9.61	24.03	-1.69%	-82.99%
ADPT	1.0B	184.3M	-2.10%	-14.96%	-5.17	5.47	19.29%	17.33%
QTRX	741.0M	104.4M	56.65%	10.37%	-8.75	7.1	-7.50%	-28.77%
NSTG	287.8M	132.0M	-37.96%	-63.90%	-1.78	2.18	-8.69%	-26.95%
HBIO	235.8M	114.5M	-2.27%	49.07%	-117.1	2.06	-5.10%	69.01%
BNGO	211.6M	29.5M	0.25%	-60.59%	-1.51	7.17	43.94%	-51.20%
CDXS	156.7M	116.2M	-40.05%	-78.73%	-3.28	1.35	-4.78%	-132.67%
PSNL	84.7M	68.7M	-20.61%	-60.48%	-0.74	1.23	-13.98%	-40.40%
CSBR	67.1M	53.7M	0.61%	-31.91%	-21.53	1.25	14.70%	-1523.74%

Financials for Quanterix

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	-1.0%	104,426,000	105,522,000	109,985,000	111,028,000	112,899,000
Gross Profit	5.1%	49,173,000	46,806,000	50,475,000	54,775,000	59,938,000
Operating Expenses	-4.3%	142,110,000	148,510,000	150,120,000	133,050,000	126,922,000
S&GA Expenses	-5.2%	87,166,000	91,995,000	101,146,000	104,850,000	98,593,000
R&D Expenses	-8.9%	23,576,000	25,890,000	28,024,000	28,200,000	28,329,000
EBITDA	1.6%	-88,955,000	-90,401,000	-73,013,000	-61,060,000	-
EBITDA Margin	-2.6%	-0.84	-0.82	-0.68	-0.54	-
Earnings Before Taxes	12.8%	-84,246,000	-96,635,000	-98,203,000	-78,839,000	-65,930,000
EBT Margin	-2.6%	-0.92	-0.89	-0.73	-0.58	-
Interest Expenses	120.1%	5,131,000	2,331,000	529,000	-188,000	-
Net Income	12.5%	-84,650,000	-96,700,000	-98,145,000	-78,742,000	-65,737,000
Net Income Margin	-2.7%	-0.92	-0.89	-0.73	-0.58	-
Free Cahsflow	10.5%	-59,998,000	-67,058,000	-66,435,000	-70,444,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-1.6%	427	434	447	489	505
Current Assets	-1.4%	376	381	387	413	434
Cash Equivalents	-1.9%	332	339	344	361	374
Inventory	1.7%	17.00	17.00	18.00	22.00	23.00
Net PPE	-5.5%	19.00	20.00	21.00	22.00	20.00
Goodwill	NaN%	-	-	9.00	9.00	-
Liabilities	-7.0%	70.00	75.00	74.00	-	-
Current Liabilities	-13.0%	27.00	31.00	29.00	37.00	32.00
Shareholder's Equity	-0.4%	357	359	373	405	426
Retained Earnings	-1.5%	-408	-402	-383	-348	-323
Additional Paid-In Capital	0.6%	768	764	759	756	751
Shares Outstanding	0.4%	37.00	37.00	37.00	37.00	37.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	25.3%	-36.08	-48.27	-54.47	-53.70	-55.51
Share Based Compensation	0.5%	16.00	15.00	17.00	18.00	16.00
Cashflow From Investing	6.6%	-10.47	-11.21	-11.80	-10.14	-9.65
Cashflow From Financing	-18.5%	2.00	2.00	1.00	-3.72	-1.54

Risks for QTRX

What is the probability of a big loss on QTRX?

100%

Probability that Quanterix stock will be more than 20% underwater in next one year

87.3%

Probability that Quanterix stock will be more than 30% underwater in next one year.

63.1%

Probability that Quanterix stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does QTRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Quanterix was unfortunately bought at previous high price.

Drawdowns

Returns for QTRX

Cumulative Returns on QTRX

1.5%

5-Year Cumulative Returns

-10.5%

3-Year Cumulative Returns

What are the long-term rolling returns for QTRX?

FIve years rolling returns for Quanterix.

Annualized Returns

Which funds bought or sold QTRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-23	ROYCE & ASSOCIATES LP	reduced	-39.71	-2,988,370	2,877,770	0.03%
2023-05-22	AMERIPRISE FINANCIAL INC	added	20.24	-255,518	11,563,500	-%
2023-05-18	JPMORGAN CHASE & CO	reduced	-6.2	-466,000	1,501,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-6.89	-199,000	622,000	-%
2023-05-16	JANE STREET GROUP, LLC	new	-	157,205	157,205	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-73.64	-1,303,580	355,940	-%
2023-05-16	PERCEPTIVE ADVISORS LLC	new	-	1,465,100	1,465,100	0.04%
2023-05-16	Rockefeller Capital Management L.P.	sold off	-100	-75,000	-	-%
2023-05-15	PDT Partners, LLC	added	103	164,645	414,984	0.06%
2023-05-15	Cubist Systematic Strategies, LLC	reduced	-22.55	-652,814	1,112,510	0.01%

Latest Funds Activity

Are funds buying QTRX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own QTRX

No. of Funds

Quanterix News

Schedule 13G FIlings of Quanterix

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 23, 2023	pura vida investments, llc	5.62%	2,080,641	SC 13G/A
Feb 14, 2023	gilder gagnon howe & co llc	2.5%	943,421	SC 13G/A
Feb 14, 2023	camber capital management lp	9.24%	2,013	SC 13G/A
Feb 14, 2023	macquarie group ltd	0.00%	0	SC 13G/A
Jan 31, 2023	blackrock inc.	7.4%	2,757,350	SC 13G/A
Jan 25, 2023	pura vida investments, llc	5.62%	2,080,641	SC 13G/A
Aug 19, 2022	camber capital management lp	8.11%	2,013	SC 13G
Feb 14, 2022	gilder gagnon howe & co llc	7.7%	2,835,999	SC 13G/A
Feb 11, 2022	macquarie group ltd	8.61%	3,154,600	SC 13G
Feb 04, 2022	blackrock inc.	6.7%	2,456,075	SC 13G

QTRX Fair Value

Show Fair-Value

Recent SEC filings of Quanterix

View All Filings

Date Filed	Form Type	Document
May 09, 2023	10-Q	Quarterly Report
May 09, 2023	8-K	Current Report
May 02, 2023	4	Insider Trading
May 02, 2023	4	Insider Trading
Apr 19, 2023	ARS	ARS
Apr 14, 2023	8-K	Current Report
Apr 14, 2023	DEF 14A	DEF 14A
Apr 14, 2023	DEFA14A	DEFA14A
Apr 04, 2023	4	Insider Trading
Apr 04, 2023	4	Insider Trading

Latest Insider Trading transactions for QTRX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-04-30	Toloue Masoud	sold (taxes)	-8,064	12.64	-638	president & ceo
2023-04-30	DOYLE MICHAEL A	sold (taxes)	-1,504	12.64	-119	cfo and treasurer
2023-04-25	Toloue Masoud	sold (taxes)	-31,310	11.67	-2,683	president & ceo
2023-04-07	DOYLE MICHAEL A	sold (taxes)	-12,705	12.63	-1,006	cfo and treasurer
2023-04-03	MEISTER PAUL M	acquired	14,999	11.16	1,344	-
2023-04-03	CRANDELL KEITH	acquired	13,057	11.16	1,170	-
2023-04-03	Hlavinka Sarah E.	acquired	14,999	11.16	1,344	-
2023-03-31	Toloue Masoud	sold (taxes)	-4,665	11.27	-414	president & ceo
2023-03-31	DOYLE MICHAEL A	sold (taxes)	-394	11.27	-35.00	cfo and treasurer
2023-02-28	DOYLE MICHAEL A	sold (taxes)	-451	11.00	-41.00	cfo and treasurer

About Quanterix

Masoud Toloue

www.quanterix.com

460

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

QTRX Income Statement

2023-03-31

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total revenue	$ 28,456	$ 29,552
Costs of goods sold:
Total costs of goods sold and services	11,530	14,993
Gross profit	16,926	14,559
Operating expenses:
Research and development	4,720	7,034
Selling, general and administrative	20,883	25,712
Other lease costs	776
Restructuring	(33)
Goodwill impairment	0	0
Impairment expense	0
Total operating expenses	26,346	32,746
Loss from operations	(9,420)	(18,187)
Interest income (expense), net	3,449	52
Other (expense) income, net	8	(217)
Loss before income taxes	(5,963)	(18,352)
Income tax (expense) benefit	(140)	199
Net loss	$ (6,103)	$ (18,153)
Net loss per share, basic (in dollars per share)	$ (0.16)	$ (0.49)
Net loss per share, diluted (in dollars per share)	$ (0.16)	$ (0.49)
Weighted-average common shares outstanding, basic (in shares)	37,326,559	36,850,894
Weighted-average common shares outstanding, diluted (in shares)	37,326,559	36,850,894
Product revenue
Total revenue	$ 19,287	$ 20,656
Costs of goods sold:
Total costs of goods sold and services	7,033	10,746
Service and other revenue
Total revenue	8,579	8,810
Costs of goods sold:
Total costs of goods sold and services	4,497	4,247
Collaboration revenue
Total revenue	368	$ 86
Grant revenue
Total revenue	$ 222

QTRX Balance Sheet

2023-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 329,354	$ 338,740
Accounts receivable (less allowance for credit losses of $222 and $118 as of March 31, 2023 and December 31, 2022, respectively)	22,546	19,017
Inventory	17,070	16,786
Prepaid expenses and other current assets	7,002	6,860
Total current assets	375,972	381,403
Restricted cash	2,920	2,597
Property and equipment, net	19,056	20,162
Intangible assets, net	7,129	7,516
Goodwill	0	0
Right-of-use assets	20,891	21,223
Other non-current assets	1,345	1,298
Total assets	427,313	434,199
Current liabilities:
Accounts payable	2,585	3,836
Accrued compensation and benefits	4,880	10,658
Other accrued expenses	4,624	4,747
Deferred revenue	10,682	8,644
Short-term lease liabilities	3,875	2,687
Other current liabilities	291	386
Total current liabilities	26,937	30,958
Deferred revenue, net of current portion	1,419	1,415
Long-term lease liabilities	40,409	41,417
Other non-current liabilities	1,216	1,469
Total liabilities	69,981	75,259
Commitments and contingencies (Note 10)
Stockholders' equity:
Common stock, $0.001 par value: Authorized shares: 120,000,000 at March 31, 2023 and December 31, 2022, respectively; Issued and outstanding: 37,423,981 shares and 37,279,994 shares at March 31, 2023 and December 31, 2022, respectively	37	37
Additional paid-in capital	768,141	763,688
Accumulated other comprehensive (loss) income	(2,581)	(2,623)
Accumulated deficit	(408,265)	(402,162)
Total stockholders' equity	357,332	358,940
Total liabilities and stockholders' equity	$ 427,313	$ 434,199